Back to Search Start Over

Activation of farnesoid X receptor promotes triglycerides lowering by suppressing phospholipase A2 G12B expression.

Authors :
Liu Q
Yang M
Fu X
Liu R
Sun C
Pan H
Wong CW
Guan M
Source :
Molecular and cellular endocrinology [Mol Cell Endocrinol] 2016 Nov 15; Vol. 436, pp. 93-101. Date of Electronic Publication: 2016 Jul 25.
Publication Year :
2016

Abstract

As a novel mediator of hepatic very low-density lipoproteins (VLDL) secretion, phospholipase A2 G12B (PLA2G12B) is transcriptionally regulated by hepatocyte nuclear factor-4 alpha (HNF-4α). Farnesoid X receptor (FXR) plays a critical role in maintaining bile acids and triglycerides (TG) homeostasis. Here we report that FXR regulates serum TG level in part through PLA2G12B. Activation of FXR by chenodeoxycholic acid (CDCA) or GW4064 significantly decreased PLA2G12B expression in HepG2 cells. PLA2G12B expression was transcriptionally repressed due to an FXR-mediated up-regulation of small heterodimer partner (SHP) which functionally suppresses HNF-4α activity. We found that hepatic PLA2G12B expression was suppressed and serum TG level reduced in high fat diet mice treated with CDCA. Concurrently, CDCA treatment lowered hepatic VLDL-TG secretion. Our data demonstrate that activation of FXR promotes TG lowering, not only by decreasing de novo lipogenesis but also reducing hepatic secretion of TG-rich VLDL particles in part through suppressing PLA2G12B expression.<br /> (Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.)

Details

Language :
English
ISSN :
1872-8057
Volume :
436
Database :
MEDLINE
Journal :
Molecular and cellular endocrinology
Publication Type :
Academic Journal
Accession number :
27471003
Full Text :
https://doi.org/10.1016/j.mce.2016.07.027